Publications by authors named "T D French"
Article Synopsis
- This study compares the cardiovascular effectiveness of different second-line antihyperglycemic agents (SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas) in patients with type 2 diabetes and cardiovascular disease.
- Using data from over 1.4 million patients across multiple databases, the researchers analyzed the risk of major adverse cardiovascular events (MACE) over a follow-up period of several years.
- Results indicated that SGLT2 inhibitors and GLP-1 receptor agonists had significantly lower risks of MACE compared to DPP-4 inhibitors and sulfonylureas, pointing to their potential superiority as treatment options for
Cervicocephalic proprioception (CCP) is an important assessment item for people with a range of clinical conditions, where reduced CCP is associated with neck pain and imbalance. Reliability has been established for a range of positional and movements tests, but there is limited data regarding sense of force, particularly across three planes of movement. The current test-retest study assessed reliability when evaluating sense of force in healthy adults (8 males, 6 females, mean age 31.
View Article and Find Full Text PDFArticle Synopsis
- * The study analyzed data from over 1.4 million patients treated with various second-line diabetes medications, using advanced statistical methods to compare outcomes and risks of heart issues.
- * Findings indicated that both SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of cardiovascular events compared to DPP-4 inhibitors and sulfonylureas, but no significant differences were found between SGLT2is and GLP1-RAs themselves regarding heart risks.
The biochemical and physical properties of a scaffold can be tailored to elicit specific cellular responses. However, it is challenging to decouple their individual effects on cell-material interactions. Here, we solvent-cast 3D printed different ratios of high and low molecular weight (MW) poly(caprolactone) (PCL) to fabricate scaffolds with significantly different stiffnesses without affecting other properties.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the adoption of second-line antihyperglycaemic medications among type 2 diabetes patients using metformin, analyzing data from 10 US and 7 international health databases.
- A total of 4.8 million participants were included, focusing on the trends in initiating additional diabetes treatments over the years 2011 to 2021.
- Results showed significant growth in the use of cardioprotective drugs (like GLP-1 receptor agonists and SGLT2 inhibitors) as second-line options, with initiation rates varying widely across countries and databases.